Takeda’s Alunbrig (brigatinib) Receives MHLW’s Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC Published: Jan 22, 2020 | Tags: Takeda, Alunbrig, (brigatinib), Receives, MHLW, Approval,1L and 2L, Treatment, ALK+ Advanced or Recurrent NSCLC MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the […]Read More
Shots: The complete dose-finding part of P-Ib/II study assessed the safety, feasibility, and RP2D of NBTXR3 (intratumoral inj.) in 20 patients with LA (T3 to T4) or unresectable rectal cancer The study showed ORR after CCRT in >70% patients, 90% patients underwent total mesorectal excision (surgery); 17.6% achieved pCR; 50% receiving surgery had good tumor […]Read More
The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased […]Read More
Shots: Nanobiotix launches a new subsidiary, Curadigm along with its Nanoprimer technology to reshape the balance b/w bioavailability, toxicity, and efficacy in the healthcare system in France & the US Nanobiotix will remain focus on its lead candidate NBTXR3 to expand radiotherapy benefits and its Immuno-Oncology program to innovate cancer immunotherapies and has also received […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
